CAS NO: | 1060524-97-1 |
包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
生物活性 | NUCC-390 is a novel and selective small-moleculeCXCR4receptoragonist. NUCC-390 induces internalization ofCXCR4receptors and acts in an opposite way of AMD3100 (HY-10046)[1][2]. NUCC-390 promotes nerve recovery of function after neurodegeneration in vivo[2]. | ||||||||||||||||
IC50& Target[1] |
| ||||||||||||||||
体外研究 (In Vitro) | NUCC-390 (10 μM) produces strong (Ca)i response, but this effect can be blocked by the known potent and selective CXCR4 antagonist AMD3100[1].NUCC-390 (10 μM; pre-treatment 30 mins) leads to increased levels of pERK, it has the capability of stimulating signaling activity downstream of CXCR4 receptors[1].NUCC-390 (10 μM; 2 hours) can induce CXCR4 receptor internalization, and non-treated cells exhibit some diffuse expression of CXCR4-YFP throughout the cytosol and clear expression in the cell membrane in HEK cells[1].NUCC-390 (0-1.25 μM; 24 hours) boosts axonal growth in cultured cerebellar granule neurons (CGNs) via CXCR4[2]. Western Blot Analysis[1]
Cell Proliferation Assay[2]
| ||||||||||||||||
体内研究 (In Vivo) | NUCC-390 (hind limb injection; 3.2 mg/kg; twice daily; 3 days) contributes to the functional and anatomical recovery of the neuromuscular junction (NMJ) following an acute nerve terminal damage by α-LTx in CD-1 mice[2].
| ||||||||||||||||
分子量 | 395.54 | ||||||||||||||||
Formula | C23H33N5O | ||||||||||||||||
CAS 号 | 1060524-97-1 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |